About Breath Therapeutics
Breath Therapeutics is a company based in Munchen (Germany) founded in 2016 was acquired by Zambon Pharma in July 2019. Breath Therapeutics has raised $46.01 million across 1 funding round from investors including Gimv, Zambon Pharma and Gilde Healthcare. Breath Therapeutics offers products and services including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions. Breath Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Munchen, Germany
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zambon Company S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.01 M (USD)
in 1 rounds
-
Latest Funding Round
$46.01 M (USD), Series A
Mar 08, 2017
-
Investors
Gimv
& 3 more
-
Employee Count
Not available
-
Acquired by
Zambon Pharma
(Jul 25, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Breath Therapeutics
Breath Therapeutics offers a comprehensive portfolio of products and services, including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions.
Inhalation therapy for Bronchiolitis Obliterans Syndrome patients
Develops intermediates for pharmaceutical industry applications
Identifies digital therapies to improve patient care outcomes
Funding Insights of Breath Therapeutics
Breath Therapeutics has successfully raised a total of $46.01M through 1 strategic funding round. The most recent funding activity was a Series A round of $46.01 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Breath Therapeutics
Breath Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gimv, Zambon Pharma and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked |
Investor details for Breath Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Breath Therapeutics
Investment portfolio details for Breath Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Breath Therapeutics
Detailed financials for Breath Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Breath Therapeutics Comparisons
Peer comparison for Breath Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Breath Therapeutics
Breath Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Breath Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Breath Therapeutics
Complete news archive for Breath Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Breath Therapeutics
Breath Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Breath Therapeutics is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Breath Therapeutics is a funded company, having raised a total of $46.01M across 1 funding round to date.
Breath Therapeutics, a spin-off of PARI Pharma, is developing inhalation therapies for delivering drugs for treating severe respiratory orphan diseases. The company is using proprietary drug formulations optimized for inhaled administration with exclusively licensed, high-performance nebulizers. Its lead product is a drug-device innovation for inhalation therapy to treat Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. The companys inhalation therapy involves a formulation of liposomal cyclosporine A for inhalation and an optimized eFlow technology nebulizer enabling remote adherence monitoring. The company has completed phase 2 trials preparing to initiate two robust Phase 3 clinical trials in the US and Europe.
Breath Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Breath Therapeutics offers Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions.
Breath Therapeutics has 4 investors. Key investors include Gimv, Zambon Pharma, Gilde Healthcare, and Sofinnova Partners.